Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Indaptus Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Indaptus Therapeutics, Inc.

INDP

Indaptus Therapeutics, Inc.

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics develops systemic immunotherapies utilizing attenuated, non-pathogenic Gram-negative bacteria to activate innate and adaptive immune responses against cancer and viral infections. Its platform aims to induce broad, durable anti-tumor and antiviral activity without targeting specific antigens, reducing systemic toxicity. The company advances clinical trials for solid tumors, collaborates on combination therapies, and seeks regulatory approval, leveraging proprietary bacterial technology to enhance immunotherapy efficacy across multiple indications.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Indaptus Therapeutics, Inc.

1
1
Indaptus Therapeutics, Inc. Indaptus Therapeutics Reports $2.5 Million Net Loss in Q1 2026, Seeks Additional Capital

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Indaptus Therapeutics, Inc. Indaptus Therapeutics Reports 2025 Financial Results and Strategic Developments

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Indaptus Therapeutics, Inc. Indaptus Therapeutics Reports Q3 2025 Financial Results with $2.98M Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Indaptus Therapeutics, Inc. Indaptus Therapeutics Reports Increased Net Loss and Decreased Total Assets for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Indaptus Therapeutics, Inc. Indaptus Therapeutics Reports $4.5 Million Net Loss in Q1 2025, Seeks Additional Capital

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Indaptus Therapeutics, Inc. Indaptus Therapeutics Reports $15M Net Loss and Decreased Operating Expenses for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Indaptus Therapeutics, Inc. Indaptus Therapeutics Reports Decline in Cash and Cash Equivalents, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments